이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

12-17세 천식 환자에서 FF/UMEC/VI와 FF/VI의 효능, 안전성 및 내약성 비교 연구

2026년 11월 3일 업데이트: GlaxoSmithKline

12-17세 참가자의 FF/UMEC/VI와 FF/VI의 효능, 안전성, 내약성 및 약동학을 비교하는 3상, 24주, 무작위, 이중 맹검, 병렬 그룹 베이지안 동적 차용 연구 ICS/LABA를 사용한 안정적인 유지 요법에서 부적절하게 조절된 천식

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

138

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Upper Hutt
      • Ebdentown, Upper Hutt, 뉴질랜드, 5018
        • GSK Investigational Site
      • Cheongju Chungcheongbuk-do, 대한민국, 28644
        • GSK Investigational Site
      • Gwangju, 대한민국, 501-757
        • GSK Investigational Site
      • Seoul, 대한민국, 05505
        • GSK Investigational Site
      • Seoul, 대한민국, 03722
        • GSK Investigational Site
      • Seoul, 대한민국, 1757
        • GSK Investigational Site
      • Seoul, 대한민국, 2447
        • GSK Investigational Site
      • Guadalajara, 멕시코, 44100
        • GSK Investigational Site
      • Monterrey, 멕시코, 64460
        • GSK Investigational Site
      • San Juan del Río, 멕시코, 76800
        • GSK Investigational Site
    • Alabama
      • Birmingham, Alabama, 미국, 35244
        • GSK Investigational Site
      • Mobile, Alabama, 미국, 36608
        • GSK Investigational Site
    • Arizona
      • Paradise Valley, Arizona, 미국, 85253
        • GSK Investigational Site
    • California
      • Bakersfield, California, 미국, 93301-4205
        • GSK Investigational Site
      • Huntington Beach, California, 미국, 92647
        • GSK Investigational Site
      • Mission Viejo, California, 미국, 92691
        • GSK Investigational Site
      • Rolling Hills Estates, California, 미국, 90274
        • GSK Investigational Site
    • Colorado
      • Colorado Springs, Colorado, 미국, 80909
        • GSK Investigational Site
    • Florida
      • Aventura, Florida, 미국, 33180
        • GSK Investigational Site
      • Miami, Florida, 미국, 33173
        • GSK Investigational Site
      • Miami, Florida, 미국, 33165
        • GSK Investigational Site
      • Miami, Florida, 미국, 33174
        • GSK Investigational Site
    • Georgia
      • Savannah, Georgia, 미국, 31406
        • GSK Investigational Site
    • Illinois
      • Normal, Illinois, 미국, 61761
        • GSK Investigational Site
    • Kentucky
      • Owensboro, Kentucky, 미국, 42301
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, 미국, 65203
        • GSK Investigational Site
    • Montana
      • Missoula, Montana, 미국, 59808
        • GSK Investigational Site
    • New York
      • The Bronx, New York, 미국, 10461-1119
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, 미국, 45229
        • GSK Investigational Site
      • Cleveland, Ohio, 미국, 44106
        • GSK Investigational Site
      • Dayton, Ohio, 미국, 45404
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73120-9350
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, 미국, 29420
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, 미국, 75225-6301
        • GSK Investigational Site
      • Kerrville, Texas, 미국, 78028
        • GSK Investigational Site
      • Plano, Texas, 미국, 75034
        • GSK Investigational Site
      • Waco, Texas, 미국, 76712
        • GSK Investigational Site
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1425BEN
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1202
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, 1888
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, 1122
        • GSK Investigational Site
      • Buenos Aires, 아르헨티나, C1023AAB
        • GSK Investigational Site
      • Córdoba, 아르헨티나, X5000DCE
        • GSK Investigational Site
      • Córdoba, 아르헨티나, X5014AKM
        • GSK Investigational Site
      • Lanus, 아르헨티나, B1824KAJ
        • GSK Investigational Site
      • Lobos, 아르헨티나, 7240
        • GSK Investigational Site
      • Lujan de Cuyo, 아르헨티나, 5509
        • GSK Investigational Site
      • Mar del Plata, 아르헨티나, 7600
        • GSK Investigational Site
      • Rosario, 아르헨티나, 2000
        • GSK Investigational Site
      • Rosario Provincia de Santa FE, 아르헨티나, 2000
        • GSK Investigational Site
      • San Miguel de Tucumán, 아르헨티나, T4000IHE
        • GSK Investigational Site
      • Santa Fe, 아르헨티나, 3000
        • GSK Investigational Site
      • Ashkelon, 이스라엘, 7830604
        • GSK Investigational Site
      • Haifa, 이스라엘, 3436212
        • GSK Investigational Site
      • Haifa, 이스라엘, 3109600
        • GSK Investigational Site
      • Petah Tikva, 이스라엘, 49202
        • GSK Investigational Site
      • Lo Barnechea, 칠레, 7691236
        • GSK Investigational Site
      • Santiago, 칠레, 7630000
        • GSK Investigational Site
      • Santiago, 칠레, 8320000
        • GSK Investigational Site
      • Adana, 터키 (Türkiye), 1173
        • GSK Investigational Site
      • Antalya, 터키 (Türkiye), 07070
        • GSK Investigational Site
      • Istanbul, 터키 (Türkiye), 34010
        • GSK Investigational Site
      • Istanbul, 터키 (Türkiye), 34899
        • GSK Investigational Site
    • Queensland
      • South Brisbane, Queensland, 호주, 4101
        • GSK Investigational Site
    • South Australia
      • North Adelaide, South Australia, 호주, 5006
        • GSK Investigational Site
    • Western Australia
      • Joondalup WA, Western Australia, 호주, 6027
        • GSK Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant must be 12 to 17 years of age (inclusive), at the time of signing the informed consent/assent.
  • Participants who have a diagnosis of asthma as defined by the National Institutes of Health [NIH, 2020] at least 1 year prior to Visit 0.
  • Participants who have required daily Inhaled corticosteroids (ICS)/ Long-Acting Beta2-Agonist (LABA) treatment for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma medications during the 6 weeks immediately prior to Visit 0 (including no changes to a stable total ICS dose of >250 to <=500 microgram (mcg)/day fluticasone propionate, or equivalent).
  • In the 1 year prior to Visit 1: A documented healthcare contact for acute asthma symptoms; OR A documented temporary change in asthma therapy for acute asthma symptoms, according to a prespecified asthma action plan (or equivalent).
  • Participants with inadequately controlled asthma (ACQ-6 score ≥1.5) at Visit 1, despite ICS/LABA maintenance therapy.
  • A best pre-bronchodilator FEV1 >40% to <=90% of the predicted normal value and a ≥12% increase in FEV1 with albuterol/salbutamol at Visit 1. Predicted values will be based on the European Respiratory Society (ERS) Global Lung Function Initiative.

Exclusion Criteria:

  • Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.
  • Any asthma exacerbation requiring a change in maintenance asthma therapy and/or the use of systemic corticosteroids for at least 3 days in the 6 weeks prior to Visit 1. (Participants requiring a temporary change in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1 provided that, at the Investigator's discretion, the participant's condition is stable after they have resumed their pre-exacerbation maintenance asthma therapy (without modification), returned to their baseline asthma status and they are considered appropriate for enrollment into this study of up to 6 months duration)
  • History of Life-threatening Asthma
  • Participants with current evidence of active pulmonary diseases or abnormalities other than asthma (e.g., pneumonia, active tuberculosis, significant bronchiectasis, etc.).
  • Current smokers and users of other inhaled products for recreation with or without nicotine (defined as participants who use cigarettes, e-cigarettes, other/vaping-related devices, cigars or pipe tobacco]) within 12 months prior to Visit 1.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: FF/UMEC/VI를 받는 참가자

FF/UMEC/VI will be administered.

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

활성 비교기: FF/VI를 받는 참가자

FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

FF/VI will be administered.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24
기간: Baseline (Week 0) and Week 24

FEV1 will be measured using spirometry.

Baseline (Week 0) and Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Asthma Control Questionnaire (7 items) (ACQ-7) (Scores on a scale)
기간: Baseline (Week 0) and Week 24

ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Change from Baseline in Asthma Control Questionnaire (6 items) (ACQ-6) (Scores on a scale)
기간: Baseline (Week 0) and Week 24

ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Change from Baseline in Asthma Control Questionnaire (5 items) (ACQ-5) (Scores on a scale)
기간: Baseline (Week 0) and Week 24

ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma.

Baseline (Week 0) and Week 24
Number of Participants with a clinically important change from baseline in ACQ-7 Score
기간: Week 24

ACQ-7 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)), a question on rescue use and an additional item relating to lung function which is calculated based on FEV1. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24
Number of Participants with a clinically important change from baseline in ACQ-6 Score
기간: Week 24

ACQ-6 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation)) and a question on rescue bronchodilator use. A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24
Number of Participants with a clinically important change from baseline in ACQ-5 Score
기간: Week 24

ACQ-5 consists of 5 symptom related questions (nocturnal awakening, symptoms on waking in the morning, activity limitation, shortness of breath and wheeze with response options ranging from zero (no impairment/limitation) to 6 (total impairment/ limitation). A score of less than or equal to (<=) 0.75 indicates well-controlled asthma and a score greater than or equal to (>=)1.5 indicates poorly controlled asthma. A change of 0.5 in score suggests a clinically important change in score.

Week 24

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: GSK Clinical Trials, GlaxoSmithKline

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 4월 24일

기본 완료 (추정된)

2027년 1월 26일

연구 완료 (추정된)

2027년 1월 28일

연구 등록 날짜

최초 제출

2023년 2월 24일

QC 기준을 충족하는 최초 제출

2023년 2월 24일

처음 게시됨 (실제)

2023년 3월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 206867

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD 공유 기간

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 공유 액세스 기준

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .